(Q39286205)

10 September 2017

title

Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers (English)

1 reference

10 September 2017

7

1 reference

10 September 2017

Judith Knievel

2

0 references

Günter Niegisch

object named as

Günter Niegisch

1

0 references

author name string

Annemarie Koch

3

1 reference

10 September 2017

Christiane Hader

4

1 reference

10 September 2017

Ute Fischer

5

1 reference

10 September 2017

Peter Albers

6

1 reference

10 September 2017

language of work or name

1 reference

1 September 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

31

1 reference

10 September 2017

issue

8

1 reference

10 September 2017

page(s)

1770-1779

1 reference

The updated EAU guidelines on muscle-invasive and metastatic bladder cancer

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Emerging targeted therapies for bladder cancer: a disease waiting for a drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

HDAC family: What are the cancer relevant targets?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Inhibition of bladder tumour growth by histone deacetylase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Decreased expression of p57(KIP2)mRNA in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Bladder cancer outcome and subtype classification by gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Histone deacetylase 8 in neuroblastoma tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Understanding urothelial carcinoma through cancer pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium [...]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Anticancer activities of histone deacetylase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Histone deacetylases: salesmen and customers in the post-translational modification market.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Class IIa histone deacetylases: regulating the regulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Transcriptional induction of MMP-10 by TGF-beta, mediated by activation of MEF2A and downregulation of class IIa HDACs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.06.015

10.1016/J.UROLONC.2012.06.015

7 January 2021

Identifiers

DOI

1 reference

release_kdzz6clzlvhn3m4p3oszf5jbxy

10 September 2017

Fatcat ID

0 references

1 reference